Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMX101 (Amzeeq) in moderate-to-severe acne vulgaris
NCT03271021Phase 3Completed
- Sponsor
- Vyne Therapeutics
- Start
- Jul 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acne vulgaris comparing FMX101 4% Foam with Vehicle Foam (2 arms). Primary endpoints: Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12 and Investigator Global Assessment (IGA) Treatment Success at Week 12. Started Jul 2017; status: completed.
02
Drugs
minocycline
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03271021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03271021.